Hamidreza Soleimani on LinkedIn: Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia… (2024)

🍛 Interesting clinical question examined here: Whether patients admitted for scheduled coronary angiography should be fasting before the procedure or not? 🇫🇷 A new study from France shows that while safety outcomes did not differ between two groups, patient comfort was higher in the non-fasting group. 🍎

35

1 Comment

An interesting study from the UK Biobank 🇬🇧 has revealed that an earlier onset of heart failure is associated with a substantial risk of developing dementia! Now that the survival rates of HF patients have improved and they live longer, it is crucial to closely monitor them for any signs of dementia. 🧠

40

🫀💻 I invite you to explore our new paper, published in International Journal of Cardiology where four machine learning models were developed for prediction of mortality after PCI. Fantastic teamwork coordinated by my dear friend Kaveh Hosseini and developed by Amir Hossein Behnoush Amirmohammad Khalaji Ali Etemadi Yeganeh Pasebani

14

CRISPR Therapeutics is presently conducting two active phase 1 clinical trials focused on in vivo gene editing for cardiovascular disorders. 🧬 One trial is dedicated to investigating the impact of gene editing on ANGPTL3 and reducing triglyceride levels while the other trial is examining the effects on Lp(a) concentrations.🔬 Encouraging results have emerged from preclinical studies involving non-human subjects.

22

🧬 Another potentially game-changing trial, exploring the applications of mRNA therapeutic agents in cardio-metabolic disorders.📉 When tested in a population of patients with TG levels > 500, Olezarsen, given monthly was able to reduce TG levels by up to a stagerring 50%! No significant side effects were reported.🔮 mRNA therapeutics are the way of the future.

32

2 Comments

Delighted to announce a new addition to our repertoire of abstract presentations at ESC 2024! With valuable inputs and expert insights from Kaveh Hosseini Adrian V. Hernandez, MD, PhD and Michael Nanna , I used R to develop a nomogram model to better predict MACE incidence in older adults with STEMI and the results were rather intriguing. Looking forward to expanding this brief abstract into a fully functional prognostic model.

37

5 Comments

🧬 RNA interference therapy is a novel pharmacologic method that promises to revolutionize the way we care for and treat chronic diseases. Tune in to this Daily Cardiology episode where I discuss Zilebesiran, an agent with tremendous potentials for improving hypertension control among individuals with uncontrolled BPs.https://lnkd.in/dBZ_ZA8e

42

It is my great pleasure to announce that our latest article has just been published in BMC Cardiovascular Disorders!In this systematic review, we examine 105 patients with a history of coronary artery dissection who experienced psycho-physical stress just before their clinical presentation. Our findings indicate that emotional stress tends to trigger SCAD more frequently in females than males, while physical stress can serve as a significant precipitating factor.This was a huge team effort and would not have been possible without the endeavours of our all star team Parisa Fallahtafti Mana Jameie Ali Ajam Narges Heydari and all others. Thanks to my dear friend Kaveh Hosseini for his terrific and ever-reliable coordination! https://lnkd.in/dzCzVce6

59

9 Comments